Bringing major cancer clinical trials to Canada through the US National Clinical Trials Network Wednesday, May 15, 2019 The Canadian Cancer Trials Group (CCTG) has been awarded more than 19 million USD over six years (approximately $25 million CAD) from the U.S. National Institutes of Health (NIH) and National Cancer Institute (NCI). This award will allow the group to continue their work leading major cancer clinical trials in Canada through the US National Clinical Trials Network (NCTN) and to develop new large scale trials under CCTG leadership. “The renewed funding will continue the US-Canadian research collaboration and allow CCTG to take the lead on a number of important trials over the next few years,” says Janet Dancey, Director of CCTG. “The partnership will support more rapid accrual to trials led by US-based groups who will be working alongside CCTG to identify better treatments for patients with cancer.” This strong partnership with US investigators within the NCTN, emphasize the need for international collaboration to conduct definitive practice-changing trials, trials in rare cancers settings, and trials testing precision-medicine strategies. CCTG has successfully obtained funding from the NCI since 1997 as a key clinical trials partner in the former US Cooperative Group Program and now with the NCTN. Read more here.
